<DOC>
	<DOCNO>NCT03059264</DOCNO>
	<brief_summary>Congenital Myotonic Dystrophy ( CDM ) multi-systemic , dominantly inherit disorder cause trinucleotide repeat expansion ( CTGn ) DMPK gene . CDM occur CTGn increase adult myotonic dystrophy type-1 ( DM1 ) parent child . Children CDM present birth respiratory insufficiency , talipes equinovarus , feed difficulty hypotonia . There 30 % mortality rate first year life . As child grow , risk intellectual impairment , autistic feature , gastrointestinal symptom , motor delay . The investigator enroll child CDM age 0-15 visit baseline one year evaluate appropriate physical functional outcome , cognitive function quality life time . Functional outcome measure correlate potential biomarkers child . Completion specific aim extend understanding disease progression CDM provide requisite information successful therapeutic trial child DM .</brief_summary>
	<brief_title>Trial Readiness Endpoint Assessment Congenital Myotonic Dystrophy</brief_title>
	<detailed_description />
	<mesh_term>Myotonic Dystrophy</mesh_term>
	<criteria>CDM Group Age 015 yr Diagnosis CDM , base symptom genetic test expand trinucleotide repeat . Any nonDM1 illness would interfere ability result study opinion site investigator Significant trauma within one month Internal metal device Control Group Age 015 yr Healthy child medication Any illness situation , opinion site investigator , possibility interfere study procedure DM type 1 2</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>